Sale!
buy Tagrisso at best price with global shipping

Tagrisso (osimertinib)

$9,300.00 $8,000.00

Tagrisso (osimertinib) is a medicine for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a T790M mutation in the epidermal growth factor receptor (EGFR) gene.

How to buy Tagrisso (osimertinib): You can order Tagrisso (osimertinib) from Cancerdrugs247 if the drug has not been approved or is not available in your country.

Oncology Lung Cancer
Marketing Authorisation Holder AstraZeneca AB
Mode of Action Kinase inhibitor (chemotherapy)
Administration Oral
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Package 30 Tablets
Compare
SKU: TAGRISSO Category: Tags: ,

Description

Buy Tagrisso (osimertinib) From Cancerdrugs247.com

Important Information

What is Tagrisso (osimertinib) for?

Tagrisso (osimertinib) is a kinase inhibitor indicated for the treatment of patients with a specific type of lung cancer (metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC))1,2,3:

  • as first-line treatment of patients whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations1,8.

  • as second line treatment of patients whose disease has progressed on or after EGFR TKI therapy1,2,3.

How does Tagrisso (osimertinib) work?

The activity of the epidermal growth factor receptor (EGFR) normally controls growth and division of cells. In lung cancer cells, the EGFR is often overactive, causing uncontrolled division of cancer cells. By blocking the EGFR, osimertinib helps to reduce the growth and spread of the cancer. Unlike most other tyrosine kinase inhibitors, Tagrisso (osimertinib) is active against cancer cells with the T790M mutation in the EGFR gene4.

Where has Tagrisso (osimertinib) been approved?

Tagrisso (osimertinib) has been approved for advanced or metastatic NSCLC in patients with epidermal growth factor receptor (EGFR) T790M mutation by the following regulatory agencies in the following regions:

  • Food and Drug Administration (FDA), USA:

    • November 13, 2015, with accelerated approval  (second-line treatment)5

    • March 30, 2017, with regular approval  (second-line treatment)6

    • April 18, 2018, as a first line treatment7

  • European Medical Agency (EMA), European Union: 

    • February 2, 2016  (second-line treatment)4
    • June 11, 2018 (first-line treatment)8
  • Therapeutic Goods Administration (TGA), Australia, August 3, 2016  (second line treatment)3

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Tagrisso (osimertinib) taken?

The standard dosage is:

  • 80 mg orally once daily

Complete information about Tagrisso (osimertinib) dosage and administration can be found in the official prescribing information listed in our resources section1,2,3.

Note: Please consult with your treating doctor for personalised dosing.

Are there any known side effects or adverse reactions of Tagrisso (osimertinib)?

Common adverse reactions

The most common adverse reactions listed in the prescribing information include1:

  • diarrhoea
  • rash
  • dry skin
  • nail toxicity
  • fatigue.

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include1:

  • interstitial lung disease (ILD)/pneumonitis
  • pneumonia
  • heart rate disturbances (QTc Interval Prolongation)
  • cardiomyopathy
  • keratitis (inflammation of the cornea of the eye).

Use in a specific population

Tagrisso (osimertinib) can be fatal for a fetus, it is advised to avoid pregnancies during treatment and for 6 weeks after the final dose. Men are advised to use effective contraception for 4 months, after the last dose1. Do not breastfeed1.

Follow the following prescription medicine precautions :

    Tagrisso may be harmful in pregnancy and there is a potential risk of miscarriage or carrying a child with birth defects if you or your partner becomes pregnant during this time. Take proper medical help in case you are pregnant, may be pregnant or planning to become pregnant in the near future.
  This medicine is not indicated for use in women. It is not known if  Tagrisso is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from Tagrisso, a decision should be made to either discontinue nursing, or discontinue the drug taking into account the importance of the drug to the mother.
  Your health care professional may recommend blood tests to see how your body is working. Blood tests help doctors check for certain diseases and conditions. They also help check the function of your organs and show how well treatments are working.
  Before taking Tagrisso, tell your doctor and pharmacist if you are allergic to  Tagrisso, any other medications, or any of the ingredients in Tagrisso injection. This medicine is not recommended for use in patients with a known allergy to Tagrisso.
  If you take Tagrisso, you must stop drinking alcohol. This is one of the ways to prevent this disease from getting worse. If you are dependent on alcohol and want to stop drinking, your doctor can recommend a therapy that’s tailored for your needs.
  If you use other prescription drugs or over the counter products at the same time, the effects of Tagrisso may change. Tell your doctor about all the drugs, vitamins, and herbal supplements you are using, so that your pharmacist can help you prevent or manage drug interactions.
  Missing a dose of Tagrisso can upset your treatment plan. If you do miss one of your doses, take it as soon as you remember, unless it’s almost time to take your next dose. In this case, you should just skip the missed dose. Don’t take a double dose to “make up” for the one you missed. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.
  Do not take Tagrisso the use by (expiry) date printed on the pack. Do not take it if the packaging is torn or shows signs of tampering. If it has expired or is damaged, return it to your pharmacist for disposal.
  During your treatment with Tagrisso, it is very important for your doctor to know about your medical history if you have Kidney problems, liver problems, HIV, triglycerides, diabetes or other health problems.

 

What are the storage instructions for Tagrisso ?

Patients must properly store the drug to retain its quality and efficacy. Following storage instructions will be helpful in storing the drug in the best of manner. 

  • Store Tagrisso at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).
  • Store it in a cool, dry place, protected from light and refrigerated when necessary. Improper storage can affect the effectiveness and shelf life of your medicine.
  • Consider storing your medications separately from your other family members. You can put them on a different shelf, or in a different cabinet or drawer.
  • If you’re driving, you may want to have certain medicines at hand, but don’t store them in the glove compartment, where they could be damaged from the heat, cold, or rain outside or from the car’s heater or air conditioner.
  • Always remember to store your medication out of sight and reach of children and pets, to prevent accidental ingestion.

Prescription Required:

cancerdrugs247.com is one of the leading suppliers of Tagrisso and has won the trust of thousands of customers by delivering Tagrisso cancer medicine at the lowest price globally. If you want to buy Tagrisso, place your order online and get them delivered at your doorsteps within the specified time-frame.

We Ship in – USA, UK, China, Canada, Russia, Australia, UAE, Singapore, Philippines, Bulgaria, Hungary, Italy, Kenya, Nigeria, Saudi Arabia, Taiwan, Zimbabwe, Malaysia, Spain, Hong Kong and many other countries.

In order to legally purchase this medicine from Cancerdrugs247.com , you’ll require a prescription from your Registered Medical Practitioner.

Note:

The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
Remember, keep this and all other medicines out of the reach of children and away from pets, never share your medicines with others, and use this medication only for the indication prescribed.

The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Reviews

There are no reviews yet.

Be the first to review “Tagrisso (osimertinib)”

Your email address will not be published.